The New Mexico Medical Psilocybin Act and current trends in the United States psychedelic policy

Abstract

In April 2025, New Mexico enacted the Medical Psilocybin Act, establishing the first legislated statewide medical psilocybin program and becoming the third state to authorize supervised psilocybin use. The Act directs the New Mexico Department of Health to build a regulated system where licensed clinicians provide psilocybin to qualified patients in approved settings for treatment-resistant depression, post-traumatic stress disorder, substance use disorders, and end-of-life care. It creates producer and clinician licensing, a nine-member advisory board, protections for individuals under community supervision, and two funds to advance equity and research. The law carves medical use out of New Mexico’s Schedule I and sets December 31, 2027 as the statutory deadline for full implementation, a date the Department of Health has since brought forward, opening producer permitting in August 2026 and targeting initial patients by the end of 2026. This health policy paper reviews this Act and situates it within a typology of U.S. psychedelic policy models of decriminalization, regulated non-medical services, and clinician-governed medical programs. It also briefly discusses Oregon’s nonmedical service model, Colorado’s healing centers, pilots in Texas and Utah, local decriminalization in Denver and Washington, FDA psilocybin breakthrough designations, veteran research, MDMA setbacks, and the federal turn marked by President Trump’s Executive Order 14401 of April 2026. It argues that New Mexico’s clinician-governed approach offers a distinctive pathway that balances wider access with clinical accountability, generating implications for federal and international discussions on psychedelic policy.